Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Raav vectors for the treatment of gm1 and gm2 gangliosidosis

A lysosomal storage disease, capsid technology, applied in the field of RAAV vectors for the treatment of GM1 and GM2 gangliosidosis

Pending Publication Date: 2021-07-23
UNIV OF MASSACHUSETTS
View PDF27 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there are no disease-modifying treatment options for Tay-Sachs disease or Sandhoff disease, and only symptomatic treatment, including anticonvulsants and antispasmodics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Raav vectors for the treatment of gm1 and gm2 gangliosidosis
  • Raav vectors for the treatment of gm1 and gm2 gangliosidosis
  • Raav vectors for the treatment of gm1 and gm2 gangliosidosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0231] Example 1: Materials and Methods

[0232] Vector design, construction and virus creation.

[0233] An AAV vector (SEQ ID NO: 3) was constructed and carried an expression cassette driven by a promoter, followed by a chimeric chicken beta-actin / rabbit beta globin intron (CBA), a mouse lysate Enzyme acid β-galactosidase cDNA (mβgal), woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and two polyA signals in tandem derived from bovine growth hormone (BGH) and SV40, the promoter by Consists of the cytomegalovirus immediate early enhancer (CMV) fused to the chicken β-actin promoter. This vector is called AAV-CBA-mβgal-WPRE. AAV-CBA-mβgalE269Q-WPRE was generated by PCR mutagenesis using the following primers: For 1 : AAA CGT CTC ACT AGT CCG CGG AAT TC (SEQ ID NO: 7), Rev 1 : AAACGT CTC ACT GAG AAT TGA TCA AA (SEQ ID NO: 7) : 8), For2: AAA GGT CTC CGG CCG CTA GCGTCA G (SEQ ID NO: 9), Rev2: AAA GGT CTC ATC AGT TCT ATA CTG GC (SEQ ID NO: 10). The res...

Embodiment 2

[0261] AAV dose-dependent distribution of βgal in the brain

[0262] The AAVrh8-CBA-mβgal-WPRE vector (Figures 1 and 20) was infused into 6-8 week old GM1 gangliosides by bilateral injection in the thalamus and deep cerebellar nucleus at total doses of 4e10vg, 2.6e10vg and 2.6e9vg, respectively storage disease mice (βgal - / - ) in the brain. Animals in the highest dose cohort received bilateral injections of 1 μl in the thalamus and DCN, while animals in the other two cohorts received 1 μl in the thalamus and 0.3 μl in the DCN. The βgal distribution pattern in the brain at 3 months post-injection appears to be dose-dependent, with the highest intensity of gal activity at the injection site ( figure 2 ). The highest dose (4e10vg) in the brain ( figure 2 A) and the cerebellum ( figure 2 Enzyme activity is provided within most of the sections in B). Moderate doses of 2.6e10vg had similar activity levels in the brain ( figure 2 E), while the cerebellum ( figure 2 F) ...

Embodiment 3

[0266] AAV treatment extends life

[0267] with untreated βgal - / - AAVrh8-treated βgal compared to control - / - Mice lived significantly longer ( Figure 4 ). untreated βgal - / - Median survival was 245.5 days for controls (N=18), 293.5 days for the 4e10vg arm (N=12, p=0.0004), 349 days for the 2.6e10vg arm (N=13, p=0.002), and 2.6e9vg arm was 389 days (N=12, p<0.0001).

[0268] GM1 ganglioside storage persists in the injection site and spinal cord of AAV-treated long-lived animals

[0269] Histological analysis of lysosomal storage by non-Ruppin staining in the animals' CNS 3 months post-injection revealed an almost complete correction in the brain and cerebellum corresponding to the presence of the enzyme, as Xgal staining at the same time point see in ( figure 2 ). Surprisingly, non-rapine-positive cells were found only at the injection site or along the injection track ( Figure 5 C, 5E).

[0270] βgal injection of AAVrh8 - / - The presence of nonruppin-positiv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

Aspects of the disclosure relate to compositions and methods for the treatment of lysosomal storage disorders, such as GM1 gangliosidosis, Tay Sachs disease, and Sandhoff disease. In some embodiments, the compositions comprise viral vectors encoding beta- galactosidase. In some embodiments, the compositions comprise viral vectors encoding beta- hexosaminidase subunits (e.g. HEXA, HEXB, or combinations thereof).

Description

[0001] Related applications [0002] This application claims filing date benefit under 35 U.S.C. §119(e) of US Provisional Application Serial No. 62 / 741,848, filed October 5, 2018, entitled "RAAV VECTORS FOR THE TREATMENT OF GM1 AND GM2 GANGLIOSIDOSIS" , U.S. Provisional Application Serial No. 62 / 814,587, filed March 6, 2019, entitled "RAAV VECTORS FOR THETREATMENT OF GM1 AND GM2 GANGLIOSIDOSIS," filed March 8, 2019, entitled "RAAV VECTORS FOR THE TREATMENT OF GM1 AND GM2 GANGLIOSIDOSIS" U.S. Provisional Application Serial No. 62 / 815,996, filed March 29, 2019 U.S. Provisional Application Serial No. 62 / 840,359, filed April 29, entitled "RAAV VECTORS FOR THE TREATMENT OF GM1 AND GM2 GANGLIOSIDOSIS," filed May 16, 2019, entitled "RAAV VECTORS FOR THE TREATMENT OF GM1 AND GM2 GANGLIOSIDOSIS" US Provisional Application Serial No. 62 / 848,858, the entire contents of each application are incorporated herein by reference. [0003] Citation of Sequence Listings Submitted Electronically ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/86C12N15/79C07K14/005
CPCC12N15/86C12N2750/14143C12N2830/42A61K48/0066A61K48/005A61P3/00A61K38/47C12Y302/01052A61K48/00C12N9/2402
Inventor M.S.埃斯特韦斯
Owner UNIV OF MASSACHUSETTS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com